APWCA clinical rounds. Evaluation of Bensal HP for the treatment of diabetic foot ulcers.
BACKGROUND: The extract of oak bark (QRB7) has been used for years as a topical medication with success. QRB7 is the proprietary oak bark extract in Bensal HP. It is indicated as an external treatment for the inflammation and irritation associated with many common forms of dermatitis, including cert...
| Publicado en: | Advances in Skin & Wound Care Vol. 21; no. 10; pp. 461 - 465 |
|---|---|
| Autores principales: | , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
2008 Oct
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105701050&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105701050 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15277941 38T jtl: Advances in Skin & Wound Care issn: 15277941 maglogo: N pubinfo: dt: 2008 Oct vid: 21 iid: 10 pid: 5086 pub: Lippincott Williams & Wilkins place: Baltimore, Maryland artinfo: ui: 105701050 105701050 2010059109 10.1097/01.asw.0000323573.57206.7b NLM18836324 105701050 ppf: 461 ppct: 4 formats: tig: atl: APWCA clinical rounds. Evaluation of Bensal HP for the treatment of diabetic foot ulcers. aug: au: Jacobs AM Tomczak R sug: subj: Diabetic Foot Drug Therapy Ointments Administration and Dosage Acids, Carbocyclic Administration and Dosage Administration, Topical Antiinflammatory Agents Administration and Dosage Clinical Trials Comparative Studies Debridement Utilization Microbial Culture and Sensitivity Tests Plant Extracts Administration and Dosage Random Assignment Salicylic Acids Administration and Dosage Silver Sulfadiazine Administration and Dosage T-Tests Wound Healing Drug Effects Wound Measurement Human ab: BACKGROUND: The extract of oak bark (QRB7) has been used for years as a topical medication with success. QRB7 is the proprietary oak bark extract in Bensal HP. It is indicated as an external treatment for the inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas, and in the treatment of insect bites, burns, and fungal infections. OBJECTIVE: To quantitatively measure the difference in diabetic ulcer size reduction when using Bensal HP versus silver sulfadiazine cream (SSC) for topical treatment as an adjunct to conventional treatment. SETTING: Private office of the primary author. METHODS: Forty diabetic patients with noncellulitic plantar Wagner grade 1 or 2 ulcers and a minimal ankle brachial index of 0.75 were randomly assigned to either the Bensal HP (QRB7) treatment group or SSC control group for 6 weeks of treatment. In addition to either Bensal HP or SSC, all wounds were cultured and treated with debridement at time 0, 2, 4, and 6 weeks and with off-loading. RESULTS: The combined wound diameter of the Bensal HP group decreased 72.5% compared to 54.7% for the SSC group. There was a statistical significance between the decreases in wound sizes after 6 weeks of treatment (P = .016). The Cohen effect size for the Bensal HP group was 2.06 compared with 1.03 for the SSC group. CONCLUSION: In this tightly controlled 6-week study in which no patients were lost to follow-up, Bensal HP seems to be an effective treatment for properly treated diabetic ulcers, outperforming an identical control group whose only difference was SSC as a medication. pubtype: Academic Journal doctype: clinical trial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|